Can I stop taking lorlatinib/lorlatinib for ten years?

Lorlatinib/lorlatinib (Lorlatinib) is a third-generation macrocyclic inhibitor of ALK and ROS1 developed to maintain the efficacy of drug-resistant ALK mutations caused by first- or second-generation ALK TKIs in non-small cell lung cancer. An early-stage clinical trial in adults with ALK- or ROS1-driven non-small cell lung cancer demonstrated objective and durable responses to single-agent loltinib, including patients with central nervous system (CNS) metastases and those previously treated with other ALK TKIs.

For patients, long-term use of lorlatinib may bring certain efficacy, but it may also be accompanied by some side effects and drug tolerance issues. Therefore, multiple factors need to be considered as to whether medication can be discontinued. The doctor will evaluate whether it is appropriate to discontinue the drug based on the patient's specific situation, including the condition, treatment effect, side effects, physical condition and other factors. If the patient's condition is stable and no serious side effects occur, the doctor may consider tapering the drug or discontinuing it. However, if the patient's condition remains severe or there is a risk of recurrence, the doctor may recommend continuing the medication or adjusting the treatment regimen.

The patient's own feelings and needs are also important considerations in drug discontinuation decisions. If a patient develops serious side effects such as nausea, vomiting, fatigue, etc. after long-term medication, and these side effects affect the quality of life, the patient can communicate with the doctor to explore the possibility of discontinuing the medication or adjusting the treatment plan.

In addition, drug tolerability issues also need to be considered when discontinuing medication. Long-term use of lorlatinib may cause the body to develop tolerance to the drug, causing the drug's effect to gradually weaken. In this case, your doctor may recommend a different medication or other treatment.